Breast imaging has gone 3-D. The FDA announced today the approval of Hologic Inc.’s Selenia Dimensions System, the first X-ray mammography device that provides 3-D images for breast cancer screening and diagnosis.
Breast imaging has gone 3-D. The FDA announced today the approval of Hologic Inc.’s Selenia Dimensions System, the first X-ray mammography device that provides 3-D images for breast cancer screening and diagnosis.
“Physicians can now access this unique and innovative 3-D technology that could significantly enhance existing diagnosis and treatment approaches,” said Jeffrey Shuren, MD, JD, director of the FDA’s Center for Devices and Radiological Health.
The device can provide two- and three-dimensional X-ray images of the breast, and the 3-D images may improve the accuracy of the detection and diagnosis of breast cancer, according to the FDA. The traditional 2-D imaging has its limitations, the FDA noted, and about 10 percent of women receive further testing after the initial screening for abnormalities later determined to be noncancerous.
The FDA reviewed results from two studies where radiologists reviewed 2-D and 3-D images from more than 300 mammography exams, according to the agency. Radiologists obtained a 7 percent improvement in their ability to distinguish between cancerous and noncancerous cases using the 3-D images, compared with 2-D.
“While the combination of the Selenia’s 2-D and 3-D images approximately doubled the radiation dose the patient received, it improved the accuracy with which radiologists detected cancers, decreasing the number of women recalled for a diagnostic workup,” the FDA said in a statement. “ There is uncertainty for radiation risk estimates; however, the increase in cancer risk from having both a 2-D and 3-D exam is expected to be less than 1.5 percent compared to the natural cancer incidence, and less than 1 percent compared to the risk from conventional 2-D mammography.”
Rob Cascella, Hologic’s president and CEO, said in a statement, "Our Dimensions 3-D takes advantage of all of the benefits of digital mammography and quite simply makes it better with the combination of fast, high quality 3-D breast imaging. We believe tomosynthesis has the potential to change how screening and diagnostic mammography is performed, and over time will prove invaluable to the earliest possible detection of breast cancer and in the reduction of unnecessary diagnostic interventions."
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Mammography Study: AI Facilitates Greater Accuracy and Longer Fixation Time on Suspicious Areas
July 8th 2025While noting no differences in sensitivity, specificity or reading time with adjunctive AI for mammography screening, the authors of a new study noted a 4 percent higher AUC and increased fixation time on lesion regions.
Can Contrast-Enhanced Mammography be a Viable Screening Alternative to Breast MRI?
June 17th 2025While the addition of contrast-enhanced mammography (CEM) to digital breast tomosynthesis (DBT) led to over a 13 percent increase in false positive cases, researchers also noted over double the cancer yield per 1,000 women in comparison to DBT alone.
Contrast-Enhanced Mammography and High-Concentration ICM Dosing: What a New Study Reveals
June 16th 2025New research showed a 96 to 97 percent sensitivity for contrast-enhanced mammography (CEM) with an increased iodine delivery rate facilitating robust contrast enhancement for women with aggressive breast cancer.